1. Introduction {#s0005}
===============

2,3,5,6-Tetramethylpyrazine (ligustrazine, TMP) is a major biologically active compound isolated from the Chinese herbal medicine *Ligusticum wallichii* Franch. TMP possesses antiplatelet activities and has been widely used in China for the treatment of patients with vascular disorders such as myocardial and cerebral infarction[@bib1]. It has been reported that TMP may provide antithrombotic effects and neuroprotection against ischemic brain injury through suppression of inflammation, blocking of calcium channels, inhibiting the formation of free radicals, and reducing the bioactivity of platelets[@bib2]. It has also been proposed to increase cerebral blood flow during ischemic brain infarction[@bib3].

The most widely used salt form of TMP in clinical therapy is TMP phosphate (TMPP). However, the absorption of TMPP after oral administration is variable and incomplete, with low bioavailability of 10%--30%[@bib4]. Intravenous infusion every 4--6 h produces a superior pharmacodynamic effect but brings poor patient compliance. Therefore, an alternative route of administration is greatly needed.

In the recent years, systemic drug delivery through the nasal route has received considerable attention[@bib5]. Intranasal (i.n.) administration offers some advantages including rapid absorption, avoidance of hepatic first-pass metabolism, and preferential drug delivery to brain *via* the olfactory region[@bib6; @bib7]. Hence i.n. delivery could be especially important in the management of crisis situations such as cerebral infarction[@bib8]. The nasal delivery of TMPP may provide a better alternative to intragastric (i.g.) and intravenous (i.v.) administration.

Microdialysis is a continuous sampling technique to study unbound drug disposition and metabolism in blood and tissues[@bib9]. Using this technique, TMP was reported to have appreciable blood--brain barrier (BBB) penetrability after i.v. administration[@bib10]. The pharmacokinetics of TMP hydrochloride following i.n. and i.v. administration also has been investigated using the brain microdialysis technique in free-moving rats[@bib11]. However, there is a limitation associated with i.n. administration in awake rats: TMPP administered nasally can be cleared from the nasal cavity into the gastrointestinal tract. Therefore, to investigate the brain pharmacokinetics of TMPP along with the plasma pharmacokinetics following i.n., i.g. and i.v. administration in parallel, our research was carried out using brain microdialysis in anaesthetized rats with a tracheotomy. These studies tested the efficacy of the nasal route of delivery, and could indicate whether there exists a direct nose-to-brain transport of TMPP. In addition, the brain pharmacokinetics of TMPP following oral administration was investigated.

2. Materials and methods {#s0010}
========================

2.1. Chemicals, reagents and animals {#s0015}
------------------------------------

Tetramethylpyrazine phosphate (TMPP) was purchased from Limin Pharmaceutical Company (Guangdong, China). Carbamazepine (internal standard, I.S.) was supplied by Hengyi Pharmaceutical Co., Ltd. (Tianjin, China). Methanol (HPLC grade) was purchased from Hanbon Sci. & Tech. Co., Ltd. (Jiangsu, China). Water was prepared in a Milli-Q water purification system (Millipore, Bedford, MA, USA). All other chemicals and reagents used were of analytical grade.

The brain microdialysis system was obtained from BAS bioanalytical systems, Inc. (Indiana, USA), and concentric microdialysis probes (MD-2204, membrane length: 4 mm, cutoff: 30 kDa) were used in this study. The artificial cerebrospinal fluid (ACSF) buffer (147 mmol/L NaCl, 4 mmol/L KCl, 2.3 mmol/L CaCl~2~) was prepared weekly, filtered, degassed and used as the perfusate[@bib12].

Male Sprague--Dawley rats weighing 200--250 g were obtained from the Experimental Animal Center of Sun Yat-sen University, and maintained on a light/dark cycle. Temperature and relative humidity were maintained at 25 °C and 50%, respectively. All care and handling of animals were approved by the Animal Ethics Committee of Sun Yat-sen University. The rats were fasted overnight (approximately 12 h) before each experiment.

2.2. Preparation of TMPP solution for administration {#s0020}
----------------------------------------------------

Dosing solution of 25 mg/mL was prepared by dissolving TMPP powder in physiological saline for the i.n. and i.v. administration, and dosing solution of 5 mg/mL was prepared by dissolving TMPP powder in distilled water for i.g. route. The preparations were made immediately prior to drug administration.

2.3. Animal experiment {#s0025}
----------------------

### 2.3.1. Experiment design {#s0030}

Thirty-six Sprague--Dawley rats randomly divided into six groups were used in this study (*n*=6), three groups for plasma PK study following i.n., i.g. or i.v. administration and the other three groups for brain microdialysis analysis of the above three delivery routes. TMPP solution was administered at a single dose of 10 mg/kg body weight (BW) to each rat.

### 2.3.2. Blood sampling and treatment for PK studies {#s0035}

The rats were anesthetized with an intraperitoneal injection of urethane (1.0 g/kg), after which tracheotomy and cannulation of the carotid artery was performed. For i.v. injection, dosing solutions were delivered using a 1 mL syringe into the femoral vein (a cannula was inserted for injection). For i.n. delivery, the esophagus and the passage of the nasopalatine duct were first occluded to prevent drug being cleared into the gastrointestinal tract[@bib12]. Then preparations were given *via* a cannula inserted 7 mm into the left cavity. Oral gavage of TMPP was performed by attaching a stainless steel feeding needle to a syringe containing the oral formulation.

A volume of 0.25 mL of blood was collected pre-dose and at time 0.033, 0.083, 0.25, 0.5, 1, 1.5, 2, 3 and 5 h post-dosing and transferred into heparinized polystyrene tubes. Plasma was separated by centrifugation at 10,000 rpm for 10 min and kept frozen at −20 °C prior to analysis.

Plasma samples were processed with the following steps: a volume of 100 μL plasma was pipetted into polystyrene tubes and 20 μL of I.S. working solution (40 μg/mL) and 1 mL water were added. The mixture was vortex mixed for 1 min and loaded onto a SPE cartridge (60 mg/3 mL, Strata-X, Phenomenex, USA), which had been conditioned by washing with methanol (1 mL) followed by water (1 mL). The sample-loaded SPE cartridge was further washed with water (1 mL) and TMPP ws eluted with 1 mL of methanol. A 20 μL aliquot of this extract was subjected to HPLC separation.

### 2.3.3. Microdialysis procedure {#s0040}

Rats were anesthetized and mounted on a stereotaxic frame, the skull was exposed and a small hole was drilled (+2.0 mm lateral to the midsagittal suture and 2.0 mm anterior to bregma). The dural and arachnoid membranes were removed to avoid damage to the microdialysis probes during their insertion into the brain. An intracerebral guide cannula was implanted, secured by screw and cement. A microdialysis probe was stereotaxically inserted *via* the guide cannula into the cerebral cortex, identically to a depth of 4.0 mm ventrally from the dura, according to the atlas of Paxinos and Watson[@bib13].

To avoid the possible influence of tissue trauma resulting from insertion of the probe on the microdialysis results, the probe was perfused with ACSF at a flow rate of 2 μL/min for 1 h to stabilize solute levels around the dialysis membrane[@bib14]. A 1 mL microsyringe was fitted to a precision pump (MD-1001) and connected to the tubing to provide the perfusate solution. Outflow from probe (dialysate) was connected to a refrigerated fraction collector (MD-1201). The rats were then held in supine position, and tracheotomy, cannulation and other procedures were completed before drug administration.

After the stabilization period, TMPP was administered at a single dose of 10 mg/kg to each rat and dialysates were collected every 10 min within 2 h and then every 20 min thereafter. 10 μL of the brain dialysate was directly injected into HPLC system and immediately analyzed after collection. Throughout the experiment, the rats were placed on heating pads to maintain body temperature at 36--37 °C. The position of the probe was verified by standard histological procedures at the end of the experiment.

2.4. Analytical method {#s0045}
----------------------

Plasma and dialysate concentrations of TMPP were measured by an Agilent 1100 HPLC system equipped with a UV detector (Agilent technologies, USA). Separations were carried out on an Elipse XDB C18 column (150 mm×4.6 mm, 5 μm, Agilent, USA) with a C18 guard column (Security Guard, Phenomenex, USA). The mobile phase consisted of water-methanol (40:60, *v*/*v*) at a flow-rate of 0.7 mL/min and the detector wavelength was set at 295 nm. The retention times of TMPP and I.S. were 3.6 min and 5.5 min, respectively. For plasma analysis, the lower limit of quantification (LLOQ) for TMPP was 20 ng/mL and the linear range was 0.08--40.96 μg/mL in rat plasma. The LLOQ value of the dialyste was 10 ng/mL and the method was linear over the concentration range from 0.02 to 1.6 μg/mL.

With the premise that *in vitro* recoveries by gain and loss are equal, *in vivo* extracellular drug concentration can be recalculated with *in vivo* probe recovery by loss[@bib15]. In the present study, *in vitro* recoveries of TMPP by gain and loss evaluated at 2.0 μL/min flow-rate with four concentration levels (0.1, 0.2, 0.4 and 0.8 μg/mL) were 30.4±2.6% and 45.1±3.0%, respectively, and were significant different (*P*\<0.05). As the recoveries of the microdialysis probes were constant, the concentrations of TMPP in dialysate measured *in vivo* were analyzed in parallel and the data were not recalculated with *in vivo* recovery to avoid deviation from actual data.

Before and at the end of the *in vivo* experiments, the *in vitro* recovery by gain of TMPP for each probe was determined by continuing the perfusion at the same settings in a calibration solution. Change in the range of 5% was accepted.

2.5. Data analysis {#s0050}
------------------

Results obtained from the HPLC analyses were plotted as concentration--time curves for plasma or brain dialysate. As the *in vitro* recoveries were similar between probes, the concentration of TMPP in cerebral cortex after different routes of administration can be compared from the drug concentration in dialysate. PK analysis was performed using the KINETICA 4.4 software. The mean area under the curve (AUC) was calculated by the trapezoidal method. The maximum concentration (*C*~max~) and the time to reach peak concentration (*t*~max~) were the observed values. Results are presented as mean values±S.D.

The degree of TMPP targeting to brain after i.n. and i.g. administration can be evaluated by the drug targeting efficiency (DTE), The higher the DTE is, the further degree of TMPP targeting to brain can be expected. DTE that represents the time average partitioning ratio was calculated as follows[@bib16; @bib17; @bib18]:$${DTE}_{i.n.} = \frac{{{(\text{AUC}}_{brain}{/\text{AUC}}_{plasma})}_{i{.n}.}}{{{(\text{AUC}}_{brain}{/\text{AUC}}_{plasma})}_{i{.v}.}}$$$${DTE}_{i.g.} = \frac{{{(\text{AUC}}_{brain}{/\text{AUC}}_{plasma})}_{i{.g}.}}{{{(\text{AUC}}_{brain}{/\text{AUC}}_{plasma})}_{i{.v}.}}$$

3. Results {#s0055}
==========

The mean plasma levels of TMPP following a single dose of i.n., i.g. and i.v. administration are shown in [Fig. 1](#f0005){ref-type="fig"}. The plasma drug concentration data were best fitted to a two-compartment open model, and the PK parameters are presented in [Table 1](#t0005){ref-type="table"}. The plasma *C*~max~ following i.n. administration was 2.8 times higher compared to that after oral delivery and the nasal bioavailability was 86.33%, 1.7 times higher than oral administration.

The unbound TMPP in the brain dialysate concentration--time profiles following i.n., i.g. and i.v. application, respectively, are presented in [Fig. 2](#f0010){ref-type="fig"}. Drug concentrations were plotted at the mid-time point of each single collection interval. Similar to other reports[@bib11], the TMPP concentration reached *C*~max~ at 15 min after i.n. and i.v. routes, faster than i.g. route (20.00±5.48 min). The brain dialysate drug concentration data were best fitted to a non-compartment open model, and selected PK parameters are presented in [Table 2](#t0010){ref-type="table"}. The ratio of the AUC~brain\ dialysates~ value between i.n. route and i.v. injection was 0.68, which was greater than that obtained after i.g. administration (0.43). The DTE of nasal route was 78.89%, close to that of i.g. route (85.69%).

4. Discussion {#s0060}
=============

For the nasal administration groups the esophagus and the passage of the nasopalatine duct were occluded under anesthesia to prevent drug from being cleared into the gastrointestinal tract and subsequently absorbed. There have been numerous pharmacokinetics studies using microdialysis sampling in anaesthetized rats[@bib19; @bib20; @bib21], so we adopted a brain microdialysis technique in anesthetic rats for our studies.

In this study, the brain dialysate was sampled by the microdialysis method with time intervals of 10 min within 2 h and then every 20 min, thereafter enabling the calculation of AUC values with sufficient time points. The tubes connecting the pump, the dialysis probe and the fraction collector were as short as possible in order to reduce the effect of the void volume on sampling time.

There have been different opinions on the damage to the BBB after insertion of a microdialysis probe. Recent publications described a biphasic response in increased BBB permeability with a prompt increase immediately after probe insertion, followed by a second increase 1--2 days after insertion[@bib22]. In this study the animals were allowed to stabilize for 1 h after probe implantation, and then each formulation was administered.

In a preliminary experiment we investigated the TMPP concentration in different parts of the rat brain using the homogenate method, and there was no significant difference between the concentration TMPP in the olfactory, cerebellum and cerebral cortex at 5 and 15 min. This was consistent with the conclusion of the study by Liang et al.[@bib23], so we chose the cerebral cortex to sample in the microdialysis experiment.

From the profiles in [Figs. 1 and 2](#f0005 f0010){ref-type="fig"}, comparison of i.n. and i.v. delivery of TMPP demonstrated that i.n. administration of TMPP achieved a much higher degree of drug delivery to brain tissue. The ratio of the AUC~brain\ dialysates~ value between i.n. route and i.v. injection was 0.68 and the bioavailability of i.n. administration was 86.33%, while the DTE was 78.89%, indicating that TMPP could be efficiently absorbed through the nasal mucosa into the systemic circulation and then delivered to the brain in rats.

The mean residence time (MRT) calculation shows that the decrease of TMPP in brain tissue was slower than that in the plasma, which was the same as the results reported by Feng et al.[@bib11]

The oral bioavailability of TMPP was lower than the nasal bioavailability (50.39% *vs.* 86.33%). This suggests that nasal absorption can circumvent the gastrointestinal tract, and may be of practical value to avoid first-pass effect frequently associated with oral administration of TMPP.

The drug uptake into the brain from the nasal mucosa can occur *via* three different pathways[@bib5]. One is that drug may be absorbed into the systemic circulation and subsequently reaches the brain by crossing the BBB. The others are the olfactory pathway and the trigeminal neural pathway by which the drug may permeate the brain directly. The extent and the route of drug delivery to the brain mainly depends on characteristics that include lipophilicity and molecular weight (MW). For a small molecular weight lipophilic drug, the rate of transport into the brain *via* the systemic pathway is rapid with the *t*~max~ usually ranging from 1 to 20 min post-dosing[@bib24; @bib25]. While small molecular weight hydrophilic drugs can be delivered into the brain *via* the olfactory pathway, with a *t*~max~ usually ranging from 30 to 60 min post-dosing and with relatively high brain bioavailability[@bib26]. Hydrophilic drugs do not easily pass the BBB from the systemic circulation after i.v. administration.

After nasal administration, TMPP reached a *C*~max~ at 15 min in brain, the DTE to the brain was 78.89%, and there was a time delay between *t*~max~ in plasma and brain. Considering the physicochemical characterization of TMPP with a MW of 252.2 and a log *P*=0.294 according to our preliminary experiment, it is probable that TMPP was mainly delivered from the nasal cavity into the systemic circulation and then taken up *via* the BBB into the brain. The potential of nasal transport can be increased with the use of absorption enhancers and more effective formulations, and a controlled release nasal formulation is under development in our lab. Intranasal administration of TMPP may be a promising alternative to traditional routes.
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###### 

Plasma pharmacokinetic parameters of TMPP after intravenous, intranasal and oral administration at a dose of 10 mg/kg (mean±S.D., *n*=6).

  Parameter                i.n.                                           i.g.                                             i.v.
  ------------------------ ---------------------------------------------- ------------------------------------------------ --------------
  *t*~max~ (min)           5.00                                           11.67±5.16                                       --
  *C*~max~ (μg/mL)         10.70±2.67[a](#tbl1fna){ref-type="table-fn"}   3.79±1.05[a](#tbl1fna){ref-type="table-fn"}      19.92±2.21
  *t*~1/2*α*~ (min)        6.60±1.80[a](#tbl1fna){ref-type="table-fn"}    13.68±3.90[a](#tbl1fna){ref-type="table-fn"}     3.12±0.60
  *t*~1/2*β*~ (min)        41.16±8.16                                     92.16±22.56[a](#tbl1fna){ref-type="table-fn"}    33.84±7.68
  MRT (min)                54.02±15.03                                    115.20±34.22[a](#tbl1fna){ref-type="table-fn"}   44.41±9.03
  AUC~0−*t*~ (μg·min/mL)   530.43±130.20                                  309.62±84.01[a](#tbl1fna){ref-type="table-fn"}   614.40±96.61
  Bioavailability (%)      86.33                                          50.39                                            --

Significantly different from i.v. group, *P*\<0.05.

###### 

Selected pharmacokinetic measures of TMPP in brain dialysate after intravenous, intranasal and oral administration at a dose of 10 mg/kg (mean±S.D., *n*=6).

  Parameter                i.n.                                           i.g.                                           i.v.
  ------------------------ ---------------------------------------------- ---------------------------------------------- --------------
  *t*~max~ (min)           15.00                                          20.00±5.48                                     15.00
  *C*~max~ (μg/mL)         0.86±0.23                                      0.29±0.10[a](#tbl2fna){ref-type="table-fn"}    1.06±0.15
  MRT (min)                82.60±19.51                                    110.42±30.30                                   101.93±24.02
  AUC~0−*t*~ (μg·min/mL)   45.12±7.34[a](#tbl2fna){ref-type="table-fn"}   28.61±6.28[a](#tbl2fna){ref-type="table-fn"}   66.25±6.69
  DTE (%)                  78.89                                          85.69                                          ---

Significantly different from i.v. group, *P*\<0.05.
